AAAAAA
Results:
1-12
|
Results: 12
Authors:
Coudert, B
Anthoney, A
Fiedler, W
Droz, JP
Dieras, V
Borner, M
Smyth, JF
Morant, R
de Vries, MJ
Roelvink, M
Fumoleau, P
Citation: B. Coudert et al., Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report, EUR J CANC, 37(17), 2001, pp. 2194-2198
Authors:
Morant, R
Citation: R. Morant, Betrifft Morant, R.: Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer. Onkologie 2001;24,116-121. Author's reply, ONKOLOGIE, 24(4), 2001, pp. 374-375
Authors:
Morant, R
Citation: R. Morant, Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer, ONKOLOGIE, 24(2), 2001, pp. 116-121
Authors:
Roth, AD
Maibach, R
Martinelli, G
Fazio, N
Aapro, MS
Pagani, O
Morant, R
Borner, MM
Herrmann, R
Honegger, H
Cavalli, F
Alberto, P
Castiglione, M
Goldhirsch, A
Citation: Ad. Roth et al., Docetaxel (Taxotere (R))-cisplatin (TC): An effective drug combination in gastric carcinoma, ANN ONCOL, 11(3), 2000, pp. 301-306
Authors:
Morant, R
Bernhard, J
Maibach, R
Borner, M
Fey, MF
Thurlimann, B
Jacky, E
Trinkler, F
Bauer, J
Zulian, G
Hanselmann, S
Hurny, C
Hering, F
Citation: R. Morant et al., Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma, ANN ONCOL, 11(2), 2000, pp. 183-188
Authors:
Sessa, C
Wanders, J
Roelvink, M
Dombernowsky, P
Nielsen, D
Morant, R
Drings, P
Wissel, P
Hanauske, AR
Citation: C. Sessa et al., Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG), ANN ONCOL, 11(2), 2000, pp. 207-210
Authors:
Pavlidis, N
Aamdal, S
Awada, A
Calvert, H
Fumoleau, P
Sorio, R
Punt, C
Verweij, J
van Oosterom, A
Morant, R
Wanders, J
Hanauske, AR
Citation: N. Pavlidis et al., Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG), CANC CHEMOT, 46(2), 2000, pp. 167-171
Authors:
Bernhard, J
Castiglione-Gertsch, M
Schmitz, SFH
Thurlimann, B
Cavalli, F
Morant, R
Fey, MF
Bonnefoi, H
Goldhirsch, A
Hurny, C
Citation: J. Bernhard et al., Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonaltreatment, EUR J CANC, 35(6), 1999, pp. 913-920
Authors:
Bernhard, J
Thurlimann, B
Schmitz, SFH
Castiglione-Gertsch, M
Cavalli, F
Morant, R
Fey, MF
Bonnefoi, H
Goldhirsch, A
Hurny, C
Citation: J. Bernhard et al., Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?, J CL ONCOL, 17(6), 1999, pp. 1672-1679
Authors:
Roth, AD
Morant, R
Alberto, P
Citation: Ad. Roth et al., High dose etretinate and interferon-alpha - A phase I study in squamous cell carcinomas and transitional cell carcinomas, ACTA ONCOL, 38(5), 1999, pp. 613-617
Authors:
Thatcher, N
De Campos, ES
Bell, DR
Steward, WP
Varghese, G
Morant, R
Vansteenkiste, JF
Rosso, R
Ewers, SB
Sundal, E
Schatzmann, E
Stocker, H
Citation: N. Thatcher et al., Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer, BR J CANC, 80(3-4), 1999, pp. 396-402
Authors:
Roth, AD
Herrmann, R
Morant, R
Borner, MM
Honegger, HP
Obrist, R
Bacchi, M
Lange, J
Alberto, P
Castiglione, M
Citation: Ad. Roth et al., Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: The SAKK experience, EUR J CANC, 34(13), 1998, pp. 2126-2128
Risultati:
1-12
|